COVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with rituximab: a cohort studyJérôme Avouac, Pierre Barbery, Christophe Richez et al.|The Lancet Rheumatology|2021Cited by 292
Microarchitectural deterioration of cortical and trabecular bone: Differing effects of denosumab and alendronateEgo Seeman, José Zanchetta, Pierre D. Delmas et al.|Journal of Bone and Mineral Research|2010Cited by 286
Differing effects of denosumab and alendronate on cortical and trabecular boneRoger Zebaze, Ego Seeman, Cesar Libanati et al.|Bone|2013Cited by 155
Risedronate Slows or Partly Reverses Cortical and Trabecular Microarchitectural Deterioration in Postmenopausal WomenYohann Bala, René Rizzoli, Roland Chapurlat et al.|Journal of Bone and Mineral Research|2013Cited by 41
Clinical trials of new drugs for the treatment of rheumatoid arthritis: focus on early diseaseJosef S Smolen, Jean‐Yves Reginster, Sabine Collaud Basset et al.|Annals of the Rheumatic Diseases|2016Cited by 30